Market Size of Mexico Oral Anti-Diabetic Drug Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 1.5 Billion |
| Market Size (2028) | USD 1.8 Billion |
| CAGR (2024 - 2029) | > 3.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Mexico Oral Anti-Diabetic Drug Market Analysis
The Mexico Oral Anti-Diabetic Drug Market size is estimated at USD 1.5 billion in 2024, and is expected to reach USD 1.8 billion by 2028, growing at a CAGR of greater than 3% during the forecast period (2024-2028).
Additionally, 11 million adults in the country have Impaired Glucose tolerance (IGT), which places them at high risk of developing type 2 diabetes. Diabetes-related health expenditure in Mexico has reached USD 20 billion, putting it in the top ten countries or territories with the highest total health expenditure. Under half (47.5%) of people living with diabetes in the country are undiagnosed.
When diabetes is undetected or inadequately treated, people with diabetes are at risk of severe and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs, leading to a greater need for access to care.
In Mexico, diabetes, especially Type 2, has become a healthcare burden as it is the primary cause of death among women and the secondary cause of death among men. Obesity, sedentarism, lousy eating habits, genetics, family background, and age are among the factors that lead to developing diabetes. Therefore, owing to the factors above, the studied market is anticipated to grow over the analysis period.
Mexico Oral Anti-Diabetic Drug Industry Segmentation
Orally administered antihyperglycemic drugs reduce blood glucose levels. Diabetes medications are employed to manage diabetes mellitus by reducing the glucose concentration in the bloodstream. Apart from insulin, the majority of GLP receptor agonists (such as liraglutide, exenatide, and others) and pramlintide are taken orally, earning them the name of oral hypoglycemic agents or oral antihyperglycemic agents. The Mexico Oral Anti-Diabetic Drug Market is segmented into drugs. The report offers the value (in USD) and volume (in Units) for the above segments.
| Oral Anti-diabetic drugs | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| ||||||
|
Mexico Oral Anti-Diabetic Drug Market Size Summary
The Mexico oral anti-diabetic drug market is poised for growth, driven by the increasing prevalence of type 2 diabetes and the associated healthcare burden. Factors such as obesity, sedentary lifestyles, and poor dietary habits contribute to the rising incidence of diabetes, making it a significant public health challenge. The market is characterized by the use of oral anti-diabetic medications, which are preferred due to their ease of use and cost-effectiveness compared to insulin. These medications, including sulfonylureas and biguanides, play a crucial role in managing blood sugar levels and preventing complications such as heart disease and kidney failure. The Mexican government's efforts to provide affordable healthcare and medications, along with public health initiatives, are expected to further stimulate market growth.
The market landscape is dominated by major pharmaceutical companies like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, which are actively involved in drug innovation and development. The availability of various classes of oral anti-diabetic drugs, each with distinct mechanisms of action, offers patients multiple options for managing their condition. Despite the challenges posed by undiagnosed diabetes and the need for ongoing medication, the market is supported by a robust healthcare infrastructure, including public insurance programs like Seguro Popular, which aim to reduce financial barriers to treatment. As the demand for effective diabetes management solutions continues to rise, the market is expected to expand, with a focus on improving patient outcomes and reducing healthcare costs.
Mexico Oral Anti-Diabetic Drug Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Oral Anti-diabetic drugs
-
2.1.1 Biguanides
-
2.1.1.1 Metformin
-
-
2.1.2 Alpha-Glucosidase Inhibitors
-
2.1.2.1 Alpha-Glucosidase Inhibitors
-
-
2.1.3 Dopamine D2 receptor agonist
-
2.1.3.1 Bromocriptin
-
-
2.1.4 SGLT-2 inhibitors
-
2.1.4.1 Invokana (Canagliflozin)
-
2.1.4.2 Jardiance (Empagliflozin)
-
2.1.4.3 Farxiga/Forxiga (Dapagliflozin)
-
2.1.4.4 Suglat (Ipragliflozin)
-
-
2.1.5 DPP-4 inhibitors
-
2.1.5.1 Onglyza (Saxagliptin)
-
2.1.5.2 Tradjenta (Linagliptin)
-
2.1.5.3 Vipidia/Nesina(Alogliptin)
-
2.1.5.4 Galvus (Vildagliptin)
-
-
2.1.6 Sulfonylureas
-
2.1.6.1 Sulfonylureas
-
-
2.1.7 Meglitinides
-
2.1.7.1 Meglitinides
-
-
-
Mexico Oral Anti-Diabetic Drug Market Size FAQs
How big is the Mexico Oral Anti-Diabetic Drug Market?
The Mexico Oral Anti-Diabetic Drug Market size is expected to reach USD 1.5 billion in 2024 and grow at a CAGR of greater than 3% to reach USD 1.8 billion by 2028.
What is the current Mexico Oral Anti-Diabetic Drug Market size?
In 2024, the Mexico Oral Anti-Diabetic Drug Market size is expected to reach USD 1.5 billion.
